-
1.
公开(公告)号:US20190185462A1
公开(公告)日:2019-06-20
申请号:US16309390
申请日:2017-06-19
发明人: Abbas Walji , Richard Berger , Craig A. Stump , Kelly Ann S. Schlegel , James J. Mulhearn , Thomas J. Greshock , Deping Wang , Mark E. Fraley , Kristen G. Jones
IPC分类号: C07D413/10 , C07D413/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D498/04 , C07D513/04 , C07D271/06 , C07D471/14 , A61P25/28 , A61P25/18 , A61P29/00 , A61P11/06 , A61P3/10 , A61P35/00 , A61P37/02
CPC分类号: C07D413/10 , A61K45/06 , A61P3/10 , A61P9/00 , A61P11/06 , A61P25/18 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , C07D271/06 , C07D271/113 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/048 , C07D491/052 , C07D498/04 , C07D513/04 , C07F7/0807
摘要: The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
-
公开(公告)号:US20190160040A1
公开(公告)日:2019-05-30
申请号:US16259754
申请日:2019-01-28
申请人: Emory University
发明人: Keqiang Ye
IPC分类号: A61K31/352 , C07D311/30 , A61K31/353 , C07D491/052 , C07D491/06 , A61K45/06 , A61K31/5377 , A61K31/407 , A61K31/4188
CPC分类号: A61K31/352 , A61K31/353 , A61K31/407 , A61K31/4188 , A61K31/5377 , A61K45/06 , C07D311/30 , C07D491/052 , C07D491/06 , A61K2300/00
摘要: In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein.
-
公开(公告)号:US20190142836A1
公开(公告)日:2019-05-16
申请号:US16244371
申请日:2019-01-10
申请人: ImmuneTarget, Inc.
发明人: Samedy Ouk , Hsiou-Chi Liou
IPC分类号: A61K31/519 , C07D495/04 , C07D491/052 , C07D491/14
CPC分类号: A61K31/519 , A61K2121/00 , C07D491/052 , C07D491/14 , C07D495/04
摘要: The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
-
4.
公开(公告)号:US20190062331A1
公开(公告)日:2019-02-28
申请号:US16176608
申请日:2018-10-31
发明人: JIANMING BAO , XIAOLEI GAO , SANDRA L. KNOWLES , CHUNSING LI, I , MICHAEL MAN-CHU LO , ROBERT D. MAZZOLA, JR. , DEBRA L. ONDEYKA , ANDREW W. STAMFORD , FENGQI ZHANG
IPC分类号: C07D471/04 , C07F9/22 , C07D519/00 , C07D491/048 , C07D471/08 , C07D491/052
CPC分类号: C07D471/04 , C07D471/08 , C07D491/048 , C07D491/052 , C07D519/00 , C07F9/222 , C07F9/6561
摘要: The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
-
公开(公告)号:US20180362497A1
公开(公告)日:2018-12-20
申请号:US15738986
申请日:2016-06-24
发明人: Hank Michael James PETRASSI , Murali Mohan Reddy PERAM SURAKATTULA , Kathrin MAEDLER , Amin ARDESTANI , Jason T. ROLAND , Tyler D. BAGULEY , Matthew S. TREMBLAY , Weijun SHEN , Peter G. SCHULTZ , Arnab K. CHATTERJEE
IPC分类号: C07D401/12 , C07D413/12 , C07D471/04 , C07D491/056 , C07D215/44 , C07D491/052 , C07D215/46
CPC分类号: C07D401/12 , A61K31/47 , A61K31/4709 , A61K31/517 , C07D215/44 , C07D215/46 , C07D413/12 , C07D471/04 , C07D491/052 , C07D491/056 , C12N9/12 , C12Y207/11001
摘要: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.
-
公开(公告)号:US20180337343A1
公开(公告)日:2018-11-22
申请号:US15945095
申请日:2018-04-04
发明人: Peter Wolohan
IPC分类号: H01L51/00 , C07D487/04 , C09K11/02 , C07D519/00 , C07D471/14 , C07D513/04 , C07D498/04 , C07D498/14 , C07D513/14 , C07D311/82 , C07D491/052 , C07F7/08 , C07D335/12 , C07D495/04 , C07D409/04 , C07D491/20 , C07D493/10 , C07D495/10
CPC分类号: H01L51/0072 , C07B59/002 , C07D311/82 , C07D335/12 , C07D409/04 , C07D471/14 , C07D487/04 , C07D491/052 , C07D491/20 , C07D493/10 , C07D495/04 , C07D495/10 , C07D498/04 , C07D498/14 , C07D513/04 , C07D513/14 , C07D519/00 , C07F7/0816 , C09K11/025 , H01L51/0067 , H01L51/0068 , H01L51/0071 , H01L51/0073 , H01L51/0074 , H01L51/0094 , H01L51/5016 , H01L51/5056 , H01L51/5072 , H01L51/5096
摘要: The present invention includes novel compounds containing heterocycles or azaheterocycles and hexaphenylbenzene or azahexaphenylbenzene. These compounds are useful as host materials for phosphorescent electroluminescent devices.
-
公开(公告)号:US20180319771A1
公开(公告)日:2018-11-08
申请号:US15770763
申请日:2016-10-20
发明人: Sara FRATTINI , Remko BAKKER , Riccardo GIOVANNINI , Giacomo FOSSATI , Dieter HAMPRECHT , Iain LINGARD , Alexander PAUTSCH , Bernd WELLENZOHN
IPC分类号: C07D401/14 , C07D471/04 , C07D487/04 , C07D405/14 , C07D491/052 , C07D498/04 , C07D498/10 , A61P3/10
CPC分类号: C07D401/14 , A61K45/06 , A61K2300/00 , A61P3/10 , C07D405/14 , C07D471/04 , C07D487/04 , C07D491/052 , C07D498/04 , C07D498/10
摘要: The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
-
公开(公告)号:US10077241B2
公开(公告)日:2018-09-18
申请号:US15303746
申请日:2015-04-14
发明人: Xuqing Zhang , Mark J. Wall , Zhihua Sui
IPC分类号: C07D405/04 , C07D413/04 , C07D235/02 , C07D403/12 , A61K31/12 , A61K31/4184 , A61K31/4188 , A61K31/423 , A61K31/427 , A61K31/5377 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/052 , A61K45/06 , C07D401/12
CPC分类号: C07D235/02 , A61K31/12 , A61K31/4184 , A61K31/4188 , A61K31/423 , A61K31/427 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D403/12 , C07D405/04 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/052
摘要: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.
-
公开(公告)号:US20180244684A1
公开(公告)日:2018-08-30
申请号:US15876909
申请日:2018-01-22
IPC分类号: C07D491/052 , A61K45/06 , A61K31/352 , C07D491/04 , A61K38/21 , A61K31/7068 , A61K31/7056 , A61K31/4188 , A61K31/7072
CPC分类号: C07D491/052 , A61K31/352 , A61K31/4188 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K38/21 , A61K45/06 , C07D491/04
摘要: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
-
公开(公告)号:US10059671B2
公开(公告)日:2018-08-28
申请号:US14765048
申请日:2014-01-22
申请人: Merck Patent GmbH
发明人: Justin Potnick
IPC分类号: C07D217/26 , C07D213/85 , C07D491/052 , C07D495/04 , A61K31/438 , A61K31/472 , A61K31/5377
CPC分类号: C07D217/26 , A61K31/438 , A61K31/472 , A61K31/5377 , C07D213/85 , C07D491/052 , C07D495/04
摘要: The present invention relates to novel substituted pyridine derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 3 (mGluR3) and/or altering glutamate level or glutamatergic signalling.
-
-
-
-
-
-
-
-
-